UCSD Researchers Develop Gene Therapy to Combat TDP-43 Neurodegeneration in Mice
Researchers at the University of California, San Diego (UCSD) have developed a gene therapy aimed at combating neurodegeneration associated with the TDP-43 protein. This protein is linked to several neurodegenerative diseases, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), and is present in over half of Alzheimer's cases. The study, published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association, details how the systemic delivery of a gene called SynCav1 to brain cells can protect cognition and preserve neuronal structure in a mouse model of TDP-43 proteinopathy. The therapy uses a modified AAV vector to deliver SynCav1, which enhances the expression of caveolin-1, a protein that supports neuronal resilience. This approach differs from traditional therapies that focus on removing toxic proteins, instead aiming to strengthen neurons' ability to withstand stress. 
